BioArctic AB (publ) (Nasdaq Stockholm: BIOA B), a Swedish research-based biopharma company, announced yesterday that it has started the first clinical study with ABBV-0805 in the United States.
US-based biopharmaceutical company, AbbVie, is responsible for the clinical development of ABBV-0805. The Phase one study in healthy volunteers will investigate the safety and tolerability of the product. It is claimed to be the most advanced within the portfolio of alpha-synuclein targeting antibodies in-licensed by AbbVie from BioArctic in December 2018. The antibody is being evaluated as a disease modifying treatment for Parkinson's disease. It is a result of a strategic research alliance between BioArctic and AbbVie focused on the development of a potential immunotherapy for Parkinson's disease.
Gunilla Osswald, PhD, CEO, BioArctic, said, 'It is gratifying that our partner AbbVie has started the first clinical trial, a Phase 1 study, with ABBV-0805. We are now looking forward to ABBV-0805 moving forward in the clinical program and developing into a therapy with the potential to provide meaningful advances for patients with Parkinson's disease.'
DNAnexus Appoints Scott Gibson as Chief Financial Officer
Takeda Touts New Exploratory Data from VARSITY Ulcerative Colitis Biologic Study
Pack Health names Kelly Brassil, PhD, RN, as director of Medical Affairs
BioArctic expects EUR15m payment from Eisai for start of BAN2401 Clarity AD study
Oncopeptides to apply for melflufen's accelerated approval with the US FDA for multiple myeloma
DelMar Pharmaceuticals adds three oncologists to Scientific Advisory Board
AbbVie withdraws phase three trial of depatuxizumab mafodotin
Infant Bacterial Therapeutics announces agreement by US FDA on design of phase III study